Bunyaviruses are significant human pathogens, causing diseases ranging from hemorrhagic 26 fevers to encephalitis. Among these viruses, La Crosse virus (LACV), a member of the California 27 serogroup, circulates in the eastern and midwestern United States. While LACV infection is often 28 asymptomatic, dozens of cases of encephalitis are reported yearly. Unfortunately, no antivirals 29 have been approved to treat LACV infection. Here, we developed a method to rapidly test potential 30 antivirals against LACV infection. From this screen, we identified several potential antiviral 31 molecules, including known antivirals. Additionally, we identified many novel antivirals that 32 exhibited antiviral activity without affecting cellular viability. Valinomycin, a potassium ionophore, 33 was among our top targets. We found that valinomycin exhibited potent anti-LACV activity in 34 multiple cell types in a dose-dependent manner. Valinomycin did not affect particle stability or 35
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infectivity, suggesting that it may preclude virus replication by altering cellular potassium ions, a 36 known determinant of LACV entry. We extended these results to other ionophores and found that 37 the antiviral activity of valinomycin extended to other viral families including bunyaviruses (Rift 38 Valley fever virus, Keystone virus), enteroviruses (Coxsackievirus, rhinovirus), flavirivuses (Zika), 39 and coronaviruses (229E and MERS-CoV). In all viral infections, we observed significant 40 reductions in virus titer in valinomycin-treated cells. In sum, we demonstrate the importance of 41 potassium ions to virus infection, suggesting a potential therapeutic target to disrupt virus 42 replication. 43 44 Importance 45 No antivirals are approved for the treatment of bunyavirus infection. The ability to rapidly screen 46 compounds and identify novel antivirals is one means to accelerate drug discovery for viruses 47 with no approved treatments. We used this approach to screen hundreds of compounds against 48 La Crosse virus, an emerging bunyavirus that causes significant disease, including encephalitis. 49
We identified several known and previously unidentified antivirals. We focused on a potassium 50 ionophore, valinomycin, due to its promising in vitro antiviral activity. We demonstrate that 51 valinomycin, as well as a selection of other ionophores, exhibits activity against La Crosse virus 52 as well as several other distantly related bunyaviruses. We finally observe that valinomycin has 53 activity against a wide array of human viral pathogens, suggesting that disrupting potassium ion 54 homeostasis with valinomycin may be a potent host pathway to target to quell virus infection. have been developed to target RVFV 9-11 , no similar effort has been invested in anti-LACV 79 therapeutics. With the increasing availability of drug panels to screen molecules for antivirals, 80 rapid investigation and deployment of antivirals for emerging viruses is possible. Several prior 81 screens for antivirals have successfully identified lead molecules and highlighted cellular 82 pathways critical to virus infection. For example, recent screens with chikungunya virus 83 highlighted berberine, abamectin, and ivermectin as promising antivirals 12 . Additionally, Zika virus 84 screens have uncovered known and novel antivirals 13-15 , including mycophenolic acid and 85 daptomycin, among others. More closely related to LACV, a RVFV screen highlighted azauridine 86 and mitoxatrone 16 . The ability to rapidly screen molecules highlights an opportunity to identify both 87 unique virus-specific and broad-spectrum antivirals, as these reports have highlighted. 88 89 Antivirals may target viral particles, viral processes and critical host-targeted antivirals 17 . Host-90 directed antivirals have gained appreciation recently, as interfering with host processes crucial to 91 viral processes has several benefits, including potential for broad-spectrum activity and a 92 heightened requirement for antiviral resistance beyond minor mutations in the virus. Additionally, 93 numerous approved and available drugs are already available that can be repurposed as 94 antivirals 18, 19 . While significant work remains to be done to identify and verify such antivirals, 95 rapidly screening compounds can provide insight. 96
97
Using the NIH's Developmental Therapeutics Program (DTP), we obtained and screened >500 98 compounds for activity against LACV. We identified several known antivirals, including 99 deoxyuridine and quinonone. Importantly, we also identified a variety of novel classes of antivirals, 100 including metal ion chelators. Valinomycin, a top hit in our screen, functions by transporting 101 potassium ions against the electrochemical gradient. We investigated the antiviral activity of 102 valinomycin, observing that valinomycin exhibits antiviral activity in several cellular systems, in a 103 dose-dependent manner and independent of treatment time. We also found that valinomycin does 104 not directly inactivate viral particles, highlighting a cellular role for potassium ions in virus infection. 105
We expanded our results to additional ionophores, observing that some but not all effectively 106 blocked LACV replication. Finally, we determined that valinomycin is broadly antiviral, as it 107 reduced replication of several viruses from diverse families, including flaviviruses and 108 enteroviruses. Together, these data highlight the utility in rapid screening of antiviral molecules 109 as well as a crucial role for potassium ions in LACV infection. 110
111

Results
112
Development of rapid screening of NIH DTP compounds active against LACV. We 113 developed a simple, rapid assay to measure antiviral activity in Huh7 cells ( Figure 1A ). We plated 114
Huh7 cells to confluency in 96-well plates, to which we added 2 µM drug from the NIH NCI Figure 1C ). This ratio highlighted several candidate antivirals, including 126 lagistase, lapachol, superacyl, and valinomycin. Interestingly, we identified several known 127 antivirals in our screen, including deoxyuridine and nelarabine (summarized in Table 1 ). Thus, 128 our assay identified molecules with novel activity against LACV, including some recognized 129 antivirals. 130 131 Valinomycin restricts LACV replication. We focused on valinomycin, as the molecule was a 132 prominent hit in our screen, had a known mechanism relevant to LACV infection, and was not 133 previously described to have antiviral activity against LACV. As an initial consideration of its 134 antiviral activity, we performed secondary screening on Huh7 cells. Cells were seeded to 135 confluency, treated with increasing doses of valinomycin, from 1 to 64 µM, and infected at MOI 136 0.1. At 48h, cells were fixed and stained with crystal violet, and stain was quantified by absorbance 137 reading. We observed that valinomycin exhibited antiviral activity at doses above 10 µM, as crystal 138 violet staining was stronger, suggesting more surviving cells ( Figure 2A ). Doses as high as 64 µM 139 did not affect crystal violet stain, suggesting that cellular viability was not compromised. To 140 confirm this phenotype with titers, we treated cells with increasing doses of valinomycin 2h prior 141 to infection at MOI 0.1 and measured titers by plaque assay at 48 hpi. We observed that viral 142 titers were significantly decreased compared to untreated controls ( Figure 2B , dotted line) at 143 concentrations above 1 µM. In fact, viral titers were reduced over 100-fold at 10 µM. We calculated 144 an IC50 value of 1.4 µM. To confirm that cellular viability was not compromised, we used a 145 fluorescent assay to measure cellular ATP content after treatment with increasing doses of 146 valinomycin. We observed cellular toxicity at doses at and above 16 µM ( Figure 2C , CC50 value 147 of 14 µM), though no toxicity was observed either by cellular morphology or fluorescent ATP assay 148 below 10 µM. 149 150 As further confirmation of valinomycin's antiviral activity, we measured cell-associated viral 151 genomes. Huh7 cells were treated and infected as above and cell-associated RNA was collected 152 at 48 hpi. RNA was purified, reverse transcribed, and analyzed via qPCR for Small, Medium, and 153
Large genome segments, normalizing to cellular β-actin. Paralleling our titer data, valinomycin 154 treatment reduced viral genome content in a dose-dependent manner ( Figure 2D ). Viral genome 155 content was reduced upwards of 100-fold with 10 µM valinomycin treatment. To extend these 156 results to other cell types, we treated and infected Vero-E6 cells as above and determined viral 157 titers by plaque assay at 48 hpi. Again, we observed a significant reduction in viral titer with an 158 IC50 value of 900 nM. In sum, our data suggest that valinomycin is antiviral at non-cytotoxic doses 159 in multiple cell types, reducing both viral titers and cell-associated viral genomes in a dose-160 dependent manner. 161
162
Valinomycin is antiviral over multiple rounds of infection. Our initial assays were performed 163 at low MOI and viral titer measured at 48 hpi. To determine if valinomycin was antiviral over 164 several rounds of replication, we treated Huh7 cells with 2 µM valinomycin two hours prior to 165 infection at MOI 0.1 and subsequently collected samples to titer every 8h for 56h total. We found 166 that LACV titers were significantly reduced at all times after 8 hpi ( Figure 3A ); in fact, virus failed 167 to replicate above input virus titers (0h). To confirm that valinomycin was reducing virus 168 replication, we measured viral RNA genomes. To this end, we treated cells with increasing doses 169 of valinomycin, infected with LACV and collected cell-associated RNA in Trizol at 24 hpi. After 170 purifying and reverse-transcribing, we performed qPCR using primers specific to the small, 171 medium, and large genome segments. We observed that treatment with valinomycin significantly 172 reduced the number of viral genomes by >90% with treatment and that no individual genome 173 segment was affected more than another ( Figure 3B ). Together, these data suggest that 174 valinomycin blocks virus replication and reduces viral RNA accumulation. 175
176
Valinomycin does not reduce viral particle infectivity. Because we observe significant 177 reductions in LACV titers with valinomycin treatment, we hypothesized that valinomycin might be 178 directly affecting cellular processes to reduce virus infection. Nonetheless, valinomycin is a cyclic 179 peptide and could potentially directly inactivate viral particles, as seen previously 20 . To test 180 whether valinomycin directly reduced virus infectivity, we directly incubated LACV with 2 µM 181 valinomycin for 24h and directly titered the surviving virus at regular intervals. We found that 182 valinomycin did not significantly alter viral titer over the time examined ( Figure 4A ), suggesting 183 that valinomycin is not directly inactivating viral particles. We further examined the capacity of 184 valinomycin to inactivate particles by incubating with increasing doses, up to 10 µM valinomycin, 185 for 24h prior to directly titering. As in our timecourse, we observed no significant change in viral 186 titers at any dose ( Figure 4B ), again suggesting that valinomycin does not directly inactivate LACV 187 particles. As final confirmation of this phenotype, we measured viral RNA in viruses exposed to 188 increasing doses of valinomycin. We then compared the relative number of genomes to the titer 189 to calculate the genome-to-PFU ratio. We observed that this number did not change with 190 valinomycin treatment, suggesting no change in specific infectivity ( Figure 4C ). In sum, these data 191 suggest that valinomycin does not affect virus infectivity by directly acting on the virion. 192
Valinomycin activity alters host cell activity. We thus hypothesized that valinomycin's antiviral 194 activity was due to its effect on the cell. The role of potassium in bunyavirus infection has been 195 well-documented, and bunyavirus entry is potassium dependent 21, 22 . To test if valinomycin was 196 affecting the cell rather than the virus, we treated Huh7 cells with 2 µM valinomycin and, 197 immediately before infection, we washed away the drug. As a control, we maintained valinomycin 198 on cells or replaced the valinomycin after washing away the initial treatment. We observed that 199 even after removing and washing valinomycin from the cells, the antiviral activity persisted, as 200 viral titers remained reduced to the same level as when valinomycin treatment is concurrent with 201 infection ( Figure 4D ). Together, these data suggest that valinomycin does not directly inactivate 202 viral particles but that treatment of cells reduces LACV infection, potentially by disrupting 203 potassium-dependent entry. 204
205
Ionophores are selectively antiviral. Given that valinomycin is a potassium ionophore, we 206 wished to investigate whether other ionophores, for potassium or otherwise, were antiviral. 207
Potassium ions play a crucial role in cellular entry; however, a role for sodium or calcium ions is 208 not as well described. Marituba virus (MTBV) infection results in a sodium ion influx 23 , but the 209 origin or function of these ionic changes are not known. To determine if other ionophores might 210 exhibit antiviral activity, we treated cells with increasing doses of nonactin (potassium and sodium 211 ionophore), nigericin (hydrogen and potassium ionophore), calcium ionophore I, and sodium 212 ionophore III ( Figure 5A ). Two hours later, we infected with LACV at MOI 0.01 and measured viral 213 titers at 48 hpi. Both nonactin and nigericin exhibited significant antiviral activity, and viral titers 214 were not measurable above 4 and 1 µM, respectively ( Figure 5B ). Treatment with sodium 215 ionophore III resulted in a dose-dependent decrease in viral titers, and virus was not recovered 216 above 10 µM. Interestingly, treatment with calcium ionophore I showed no changes in viral titer, 217 even at the highest dose. Thus, we observe that LACV replication is disrupted by several 218 ionophores, especially potassium ionophores, highlighting the role for potassium in virus infection. 219 220 Valinomycin is broadly antiviral. LACV is related to several other medically-relevant 221 bunyaviruses, including Keystone virus and Rift Valley fever virus. To determine whether these 222 viruses respond to valinomycin treatment, we treated and infected Huh7 cells with these viruses 223
and measured viral titers at 48 hpi. As with LACV, we observed a dose-dependent decrease in 224 viral titers, with titers decreasing greater than 100-fold at concentrations above 2 µM ( Figure 6A ). 225
To expand beyond bunyaviruses, we performed the same analysis with Zika virus (flavivirus) 226 infection ( Figure 6B) , Coxsackievirus B3 and human rhinovirus 2 (picornaviruses) (Figure 6C Valinomycin is a naturally occurring cycling peptide, synthesized by Streptomyces species as an 259 antibiotic 25 . In our assays, we did not observe significant cellular toxicity, as measured either by 260 gross cellular morphology or by measuring cellular ATP levels, until doses above 10 µM, while 261 our IC50 of 1.4 µM suggests there is a window of therapeutic potential. However, given the drug's 262 toxicity in vivo, modification of the valinomycin structure may tune toxicity while maintaining 263 antiviral activity. Additionally, using other, less toxic potassium ionophores may similarly function 264 to inhibit LACV infection, as we observed with nonactin and nigericin. For outbreak viruses like 265 SARS CoV or ZIKV, however, limited valinomycin usage might be beneficial. Interestingly, 266 valinomycin was identified in an earlier screen for anti-SARS-CoV molecules 26 , underscoring the 267 antiviral potential of valinomycin despite its negative characteristics. Importantly, the emergence 268 of a new group 2B CoV, nCoV-2019 signals the ongoing threat and need to rapidly respond to 269 novel emergent virues. Additional in vivo testing, combined with medicinal chemistry approaches 270 to structural modification, would be necessary prior to clinical use. 271
272
In addition to valinomycin, our screen identified several tantalizing antiviral candidates. In fact, 273 several known antivirals were identified (summarized in Table 1 ). Dasatinib has previously been 274 described to inhibit dengue virus and HIV infection 27,28 . Quininone has activity against enterovirus 275 proteases as well as reverse transcriptases 29, 30 . As mentioned previously, mitoxantrone was 276 identified in a screen for anti-RVFV molecules 16 
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